KRTX — Karuna Therapeutics Share News
0.000.00%
Last trade - 00:00- $12.58bn
- $11.32bn
- $0.65m
Karuna Therapeutics surges on buyout deal by Bristol Myers
Brief: Bristol Myers Squibb To Buy Karuna Therapeutics For $14 Bln
Bristol Myers to buy Karuna Therapeutics for $14 billion - WSJ (updated)
Bristol Myers to buy Karuna Therapeutics for $14 billion - WSJ
Brief: Bristol Myers To Buy Karuna Therapeutics For $14 Bln - WSJ
Health Rounds: Schizophrenia drug using new approach shows promise in trial
Brief: Karuna Therapeutics Announces The Lancet Publication Of Data From Phase 3 Emergent-2 Trial Evaluating Karxt In Schizophrenia
U.S. STOCKS ON THE MOVE-Canadian Solar, Domino's, tech stocks
AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say
Karuna Therapeutics falls as rival Cerevel snapped up by AbbVie
Jefferies says biotech may see more M&A deals in 2024
Karuna Therapeutics up on additional safety data on schizophrenia drug
Karuna Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Karuna Therapeutics Inc expected to post a loss of $2.74 a share - Earnings Preview
Brief: Karuna Therapeutics Submits New Drug Application To US FDA For Karxt For The Treatment Of Schizophrenia
Karuna Therapeutics falls on wider Q2 loss
Karuna Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Karuna Therapeutics Announces Leadership Appointments
Karuna Therapeutics Inc expected to post a loss of $2.78 a share - Earnings Preview